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Abstract
Humans and mice lacking functional caspase-8 in T cells manifest a profound immunodeficiency 
syndrome due to defective T cell antigen receptor (TCR)-induced NF-κB signaling and 
proliferation. It is unknown how caspase-8 is activated following T cell stimulation, and what is 
the caspase-8 substrate(s) that is necessary to initiate T cell cycling. We observe that following 
TCR ligation, a small portion of total cellular caspase-8 and c-FLIPL rapidly migrate to lipid rafts 
where they associate in an active caspase complex. Activation of caspase-8 in lipid rafts is 
followed by rapid cleavage of c-FLIPL at a known caspase-8 cleavage site. The active caspase·c-
FLIP complex forms in the absence of Fas (CD95/APO1) and associates with the NF-κB signaling 
molecules RIP1, TRAF2, and TRAF6, as well as upstream NF-κB regulators PKCθ, CARMA1, 
Bcl-10, and MALT1, which connect to the TCR. The lack of caspase-8 results in the absence of 
MALT1 and Bcl-10 in the active caspase complex. Consistent with this observation, inhibition of 
caspase activity attenuates NF-κB activation. The current findings define a link among TCR, 
caspases, and the NF-κB pathway that occurs in a sequestered lipid raft environment in T cells.
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Activation of caspases has traditionally been associated with oligomerization of death 
receptors and induction of cell death (1). It has been determined more recently that caspase 
activity is also required for the induction of proliferation by primary naïve human and 
murine T cells (2–4). Inhibition of caspase activity by the pan-caspase blocker, Z-VAD-fmk,
4
 or the caspase-8-specific blocker, IETD-fmk, greatly reduced production of IL-2 and 
proliferation following TCR ligation (2, 3). It was subsequently shown that a non-functional 
mutation in the caspase-8gene in humans (5, 6) or the deletion of caspase-8in murine T cells 
(7) resulted in an immunodeficiency syndrome characterized by markedly decreased 
production of IL-2 and proliferative capacity of T cells.
It remained uncertain from these studies how caspase activation was linked to T cell antigen 
receptor (TCR) ligation, what were the regulatory protein(s) and substrate(s) of caspase 
activity, and whether this required the presence of the death receptor Fas (CD95/APO1). 
Equally puzzling was how the activation of caspase-8 might be limited to avoid induction of 
apoptosis. We recently observed that following T cell activation, cleavage occurs of certain 
known caspase substrates, such as c-FLIP-Long form (c-FLIPL) and RIP1, although another 
caspase-8 substrate associated with cell death, Bid, was not cleaved (4). This suggested that 
active caspase-8 may become sequestered in a specific site within T cells after activation.
We considered the possibility of c-FLIPL as both an activator of caspase-8 and an early 
caspase-8 substrate after T cell activation. c-FLIPL is homologous to caspase-8 in containing 
two death effector domains, but bears a mutation in the caspase domain, which renders it 
enzymatically inactive (8). Following ligation of Fas, c-FLIPL is co-recruited with caspase-8 
to the death-inducing signal complex (1, 8). In addition, c-FLIPL is able to directly 
heterodimerize with and activate caspase-8 in its full-length form, independently of Fas (9–
11). c-FLIPL, furthermore, contains a caspase cleavage site at Asp376 that yields processed 
p43 FLIP (12, 13). Assuch, c-FLIPL may be an early caspase-8 substrate during T cell 
4The abbreviations used are:
Z benzyloxycarbonyl
fmk fluoromethyl ketone
c-FLIPL c-FLIP-Long form
TCR T cell antigen receptor
MBCD methyl-β-cyclodextran
IL interleukin
MALT1 mucosa-associated lymphoid tissue translocation protein 1
CARMA1 caspase-recruitment domain membrane-associated guanylate kinase protein 1
PBS phosphate-buffered saline
TRAF tumor necrosis factor receptor-associated factor
LAT linker for activation of T cells
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activation. c-FLIPL also associates with RIP1 and TRAF2 to promote activation of NF-κB 
(14). Mice overexpressing c-FLIPL in the T cell compartment manifest augmented IL-2, and 
enhanced proliferation (15, 16). Collectively, c-FLIPL may provide an important link in our 
understanding of how TCR stimulation activates caspase-8, what is the caspase-8 
substrate(s), and how caspase activity may link to NF-κB activation.
Recent reports indicate that the para-caspase, mucosa-associated lymphoid tissue 
translocation protein 1 (MALT1), B cell lymphoma protein 10 (Bcl-10), and caspase-
recruitment domain membrane-associated guanylate kinase protein 1 (CARMA1) form a 
complex that is required for TCR-mediated NF-κB activation (17–22). MALT1 is regarded 
as a para-caspase as it contains a caspase-like domain, although actual caspase activity has 
not been demonstrated as MALT1 does not bind any known caspase substrates (23). Given 
the similar phenotypes between caspase-8-deficient mice (7) and mice deficient for MALT1 
(20), Bcl-10 (21, 22), or CARMA1 (17–19), we explored a potential link between caspase-8 
activation and the MALT1 complex. Because CARMA1, Bcl-10, and MALT1 localize to 
lipid rafts upon TCR stimulation, we considered that the active caspase complex we had 
previously defined in activated T cells (15) might form in lipid rafts and be connected with 
CARMA1, Bcl-10, and MALT1.
In the current study, we demonstrate that resting T cells manifest low to negligible levels of 
active caspase-8, but this increases following activation of T cells in association with lipid 
rafts. TCR-induced caspase-8 activation occurs rapidly and in the absence of Fas expression. 
Concomitant with cleavage of c-FLIPL to p43 FLIP is the association of the active caspase 
complex with several members of the NF-κB activation pathway, including PKCθ, 
CARMA1, Bcl-10, MALT1, as well as RIP1, TRAF2/6, and the IKKα/β/γ complex. These 
findings provide new insights into the mechanisms of TCR-induced caspase activation, and 
how this links to NF-κB pathway.
EXPERIMENTAL PROCEDURES
Mice
C57BL/6 wild-type mice, B6 transgenic mice expressing c-FLIPL in the T cell compartment 
(c-FLIPL-Tg) (16), their non-transgenic littermate controls, B6lpr mice, NF-κB reporter 
mice (24), and T cell conditional caspase-8-deficient (tcasp8−/−) mice (7) were housed and 
bred in the University of Vermont animal facility and used at 2–6 months of age. The animal 
facility is AALAC-approved, and protocols were approved by the University of Vermont 
College of Medicine IACUC. Original breeding pairs of C57BL/6 and B6lpr mice were 
obtained from the Jackson Laboratories (Bar Harbor, ME). Bcl-10-deficient mice (21) were 
housed at The Blood Center of Wisconsin and MALT1-deficient mice (22) were housed at 
the Technical University of Munich. The NF-κB-luciferase reporter mice have the luciferase 
gene controlled by two copies of KB sequences from the IgK enhancer (25).
T Cell Purification
Spleen and lymph node cells were isolated and disrupted through nylon mesh in RPMI 1640 
with 25 mM Hepes (MediaTech, Herndon, VA) containing 5% (v/v) bovine calf serum 
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(HyClone, Logan, UT). Erythrocyte lysis of splenocytes was performed using Geys solution. 
T cells were purified using negative selection by incubating splenocytes with anti-MHC II 
(M5/114/15/2), anti-CD11b (M1/70), anti-NK1.1 (PK136), and anti-B220 (RA3-6B2) on ice 
for 30 min. Cells were washed three times and rocked with goat anti-mouse and goat anti-rat 
conjugated magnetic beads at a 10:1 ratio of beads to cell (Qiagen, Valencia, CA) at 4 °C for 
45 min. Magnetic depletion was used to remove bead-bound cells. Cells were washed and 
resuspended in culture medium (RPMI 1640, 2.5 mg/ml glucose (Sigma), 10 mg/ml folate 
(Invitrogen), 110 µg/ml pyruvate (Invitrogen), 5 × 10−5M 2-mercaptoethanol (Sigma), 292.3 
µg/ml glutamine (Invitrogen), 100 units/ml penicillin-streptomycin (Invitrogen), and 5% 
fetal calf serum).
T Cell Culture
C57BL/6 and c-FLIPL-Tg T cells were activated in culture medium by plate-bound anti-
CD3 (10 µg/ml, clone 145–2C11), anti-CD28 (clone 37.51) ascites (1:500), and recombinant 
human IL-2 (50 units/ml, Cetus, Emeryville, CA) for 2 days. Cells were then removed from 
anti-CD3 and supplied with fresh medium plus IL-2. For short-term activation studies, T 
cells were stimulated with soluble anti-CD3 (20 µg/ml) cross-linked with goat anti-hamster 
IgG (50 µg/ml, Caltag, Invitrogen) for 30 or 60 min. Purified CD8+T cells were activated 
with anti-CD3 (5 µg/ml) and anti-CD28 (1:500 dilution of ascites). To measure NF-κB-
luciferase activity, anti-CD3/CD28-activated T cells from NF-κB-luciferase transgenic mice 
were harvested after 48 h, washed with PBS, and lysed. The lysates were then analyzed 
using luciferin (Promega Corp., Madison, WI) and measured in a luminometer for 10 s. Four 
measurements were made for each sample. Results are presented as the mean (± S.E.) with 
background subtracted.
CFSE Dye Labeling of Cells
Cells were washed with PBS plus 0.1% bovine serum albumin, and then mixed with 5 µM 
CFSE (Molecular Probes) in PBS plus 0.1% bovine serum albumin. Cells were labeled at 
107/ml for 10 min at 37 °C. Cells were then washed three times. A portion of the cells was 
incubated overnight at 37 °C to serve as a non-cycling control for flow cytometry, and the 
remaining cells were stimulated.
Immunoblot Analysis
T cells were lysed in buffer containing 0.2% Nonidet P-40, 20 mM Tris-HCl (pH 7.4) 
(American Bioanalytical, Natick, MA), 2 mM sodium orthovanadate (Sigma), 10% glycerol 
(Fisher), 150 mM NaCl (Sigma), complete protease inhibitor (Roche Diagnostics), and 20 
µM z-VAD-fmk (MP Biomedicals). Protein concentration was determined by Bradford 
assay (Bio-Rad). Protein lysates were boiled for 5 min in loading buffer containing 2-
mercaptoethanol and separated using SDS-PAGE on 8, 10, or 12.5% gels. Proteins were 
transferred onto polyvinylidene difluoride membranes (Bio-Rad) and blocked using 4% milk 
in Tris-buffered saline plus 0.1% Tween 20 (American Bioanalytical) at room temperature 
for 1 h. Membranes were incubated at 4 °C overnight in milk containing one of the 
following primary detection antibodies: paxillin (clone 165, BD Biosciences), cholera toxin 
B subunit (Sigma), Bcl-10 (clone H-197, Santa Cruz Biotechnology, Santa Cruz, CA), 
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CARMA1 (catalog number 3189, ProSci, Poway, CA), caspase-8 (a kind gift of Dr. Andreas 
Strasser, The Walter and Eliza Hall Institute of Medical Research, Melbourne, Australia), 
IKKα (catalog number 2682, Cell Signaling Technology, Beverly, MA), IKKβ (catalog 
number 2684, Cell Signaling Technology), IKKγ (clone FL-419, Santa Cruz), LAT (catalog 
number 06-807, Upstate Biotechnology, Lake Placid, NY), RIP1 (clone 38, BD 
Biosciences), TRAF2 (catalog number 592, MBL, Woburn, MA), TRAF6 (catalog number 
597, MBL), FLIP (clone Dave-2, Axxora, San Diego, CA), and MALT1 (C terminus-
specific, a generous gift from Dr. Vishva Dixit, Genentech, South San Francisco, CA). 
Immunoreactive proteins were visualized using horseradish peroxidase-labeled conjugates 
(Santa Cruz; Southern Biotech, Birmingham, AL; Biomeda, Foster City, CA; and Jackson 
ImmunoResearch) and developed using LumiGLO (KPL, Gaithersburg, MD). Immunoblot 
membranes were treated with azide, washed, and reprobed with another antibody to ensure 
valid comparisons among the same set of samples.
Biotin-VAD-fmk Treatment and Caspase Precipitation Assay
T cells were incubated in culture medium plus recombinant human IL-2 with 10 µM biotin-
VAD-fmk (MP Biomedicals) at 37 °C for 15 min. As a negative control, a portion of T cells 
was incubated with 100 µM non-biotinylated z-VAD-fmk prior to incubation with biotin-
VAD-fmk (not shown). Cells for unfractionated lysates were lysed in buffer containing 20 
µM biotin-VAD-fmk. 600 µg of unfractionated lysate or 800 µl of cytosolic and lipid raft 
fractions (see below) were precleared by rocking with 40 µl of Sepharose 6B-agarose beads 
(Sigma) at 4 °C for 2 h. Supernatants were then rocked with 60 µl of streptavidin-Sepharose 
beads (Zymed Laboratories Inc. and Invitrogen) at 4 °C overnight. Beads were washed 5 
times in lysis buffer without protease inhibitor, then boiled in loading buffer. Beads were 
removed by centrifugation and immunoblot analysis was then performed on supernatants.
Lipid Raft and Cytosolic Fraction Isolation
As described previously, T cells were washed twice in cold PBS, then lysed in TNE buffer 
(5 mM iodoacetic acid (Pierce), 150 mM NaCl, 15 mM EDTA (Sigma), 10 mM Tris-HCl 
(pH 7.4)) supplemented with 0.5% Triton X-100, and 100 mM Na2CO3 (Sigma) for 30 min 
on ice (26). Lysates were then sonicated three times for 10 s each and rested on ice for 10 
min. Lysates were mixed with Opti-Prep™ sucrose substitute (Sigma) to a final 
concentration of 40%. OptiPrep was diluted to 30 or 5% by mixing with TNE buffer. The 
40% OptiPrep/cell lysate mixture was placed in an ultracentrifuge tube and the 30 and 5% 
solutions were layered over the 40% solution. Gradients were centrifuged overnight at 4 °C 
at 200,000 × g. Twelve sequential 1-ml fractions were taken, starting with the top layer. A 
portion of each fraction was used for active caspase precipitation and another portion was 
used for immunoblot analysis.
Caspase Activity Assay
Relative caspase activities were determined using the Apo-ONE Caspase-3/7 Assay 
(Promega). Fresh or day 4 effector T cells were resuspended in culture medium at 10 × 
106/ml. Cells were serially diluted in culture medium and then mixed with 100 µl of caspase 
reagent (DEVD-rhodamine) according to the manufacturer’s protocol. Spectrophotometric 
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readings were taken over a range of times. The data shown represent readings at 5 h for 
fresh and 90 min for effector populations.
Cholesterol Depletion
Fresh and day 4 wild-type effector T cells were washed with serum-free medium, 
resuspended in serum-free media containing glucose, 2-mercaptoethanol, and 1.5% fatty 
acid-free bovine serum albumin (Sigma), and warmed for 10 min at 37 °C. Cells were then 
treated with methyl-f3-cyclodextran (MBCD, Sigma) at a final concentration of 20 mM for 
10 min at 37 °C. Cells were washed with fatty acid-free bovine serum albumin media, and 
lipid rafts isolated. Fresh cells were then activated using soluble anti-CD3 cross-linked with 
goat anti-hamster IgG for 60 min. Following MBCD treatment fresh, 60-min stimulated and 
effector T cells were washed with room temperature PBS prior to lysis in biotin-VAD-fmk-
containing buffer.
RESULTS
Active Caspase-8 and c-FLIP Are Found in Lipid Rafts of Activated T Cells
The levels of total cellular caspase-8 are equivalent between resting and effector T cells, and 
caspase-8 activation following TCR stimulation does not result in cell death but rather, is 
necessary to initiate cell cycling (3, 4). To achieve separation of caspase-mediated death 
from proliferation, we considered whether TCR-initiated caspase-8 activation might occur in 
a sequestered location. Because many signaling events triggered by TCR activation occur in 
lipid rafts, and lipid rafts are stable through the effector T cell stage (27), we examined the 
possible migration of caspase-8 and c-FLIPL to this compartment. Cell lysates were mixed 
with OptiPrep sucrose substitute and overlaid with a discontinuous OptiPrep gradient 
followed by ultracentrifugation overnight (see “Experimental Procedures” for details). 
Twelve 1-ml fractions were taken and immunoblots performed for paxillin, a non-raft 
cytosolic component, and the ganglioside, GM1, which localizes in part to lipid rafts in 
resting T cells (Fig. 1A) (28). Based on these reference molecules, fractions 3 and 4 were 
observed to contain lipid rafts, whereas fractions 9–12 contained the cytosolic components 
(Fig. 1A, top panels).
Examination of fresh wild-type T cells revealed that essentially all caspase-8 and c-FLIPL 
were localized to the non-raft cytosolic fractions. Fresh c-FLIPL-Tg T cells contained a 
small but reproducibly detectable amount of caspase-8 and c-FLIPL in the lipid raft 
fractions. This parallels previous observations that resting c-FLIPL-Tg T cells manifest 
spontaneous caspase activity (15), and that c-FLIPL heterodimerizes with and activates 
caspase-8 (10, 29). In contrast to fresh T cells, day 4 effector T cells from both wild-type 
and c-FLIPL-Tg T cells manifested within the lipid raft fraction increased an amount of full-
length and processed caspase-8 and c-FLIPL. Both caspase-8 and c-FLIPL contain known 
caspase-8 cleavage sites in their C-terminal domains that yield processed p43 caspase-8 and 
p43 FLIP (10). Notably, the relative proportion of processed to uncleaved caspase-8 and c-
FLIP was substantially higher in the lipid raft fraction compared with the cytosolic 
component of effector T cells (Fig. 1A).
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These findings suggested that active caspase-8 might be enriched in the raft fraction. To 
examine this more definitively, wild-type fresh and day 4 effector T cells were treated with 
biotin-VAD-fmk prior to lysis and then fractionated into raft and cytosolic components. 
Protein content in lipid rafts from fresh and effector populations was comparable (data not 
shown). Fractions were then individually precipitated with streptavidin-Sepharose beads, 
separated by SDS-PAGE, and immunoblotted to reveal active caspase-8. As shown in Fig. 
1B, no active caspase-8 was detected in fresh T cells in either the raft or cytosolic fractions. 
However, in day 4 effector T cells, both active full-length caspase-8 and p43 caspase-8 were 
precipitated exclusively from lipid raft fraction 4 (Fig. 1B), even though the vast majority of 
caspase-8 still resided in cytosolic fractions 10 and 11 (Fig. 1A, lower left panels). In 
addition, c-FLIPL co-precipitated with the active caspase complex in lipid rafts, the majority 
of which was processed to p43 FLIP despite the reverse ratio in the whole cell lysate (Fig. 
1B, lower panel). This is consistent with the view that caspase activity was concentrated in 
the lipid raft fraction. Thus, c-FLIPL and caspase-8 migrate to lipid rafts following TCR 
ligation, and this accompanies the activation of caspase-8 and cleavage of c-FLIPL.
NF-κB Signaling Molecules Migrate to Lipid Rafts and Associate with Active Caspases
We (15) and others (30) have previously observed that processed p43 FLIP can associate 
with the adaptor proteins, TRAF2 and RIP1, to promote activation of NF-κB. An additional 
pathway linking TCR triggering to NF-κB activation has been defined more recently to 
include PKCθ, CARMA1, MALT1, and Bcl-10 (31). Given that caspase activity is 
necessary for optimal NF-κB signaling in T cells (6, 15), we examined whether members of 
the TCR-mediated NF-κB signaling machinery, PKCθ, CARMA1, MALT1, and Bcl-10, co-
localized with active caspase-8 and c-FLIP in lipid rafts. Lipid raft and cytosolic fractions 
were thus prepared from wild-type fresh and day 4 effector T cells and immunoblotted for 
molecules linked to the NF-κB pathway. As with caspase-8 and c-FLIPL, the major portion 
of most of these molecules was located in the cytosolic compartment of fresh T cells and 
they were not precipitated with biotin-VAD-fmk (data not shown). In contrast, day 4 
effector T cells contained within the lipid raft compartment a portion of total cellular PKCθ, 
CARMA1, MALT1, and Bcl-10 (Fig. 2A, left panels). The lipid rafts of effector T cells also 
contained portions of adaptor proteins RIP1, TRAF2, and TRAF6, as well as members of the 
IKK complex, IKKα, IKKβ, and IKKγ (Fig. 2A, left panels). Of note is that the size of 
TRAF2 as well as TRAF6 differed between the lipid raft and cytosolic fractions. This might 
represent differences in the known ubiquitination of these molecules (32–34), as a spread of 
low to higher molecular weight forms of TRAF2 and TRAF6 were faintly visible in the lipid 
raft fractions. Thus, lipid rafts from effector T cells contained much of the machinery for 
activation of NF-κB in close proximity with active caspase-8.
Because several members of the NF-κB pathway co-localized with caspase-8 in lipid rafts, 
we examined whether these molecules actually associated with active caspases. Effector T 
cells were labeled with biotin-VAD-fmk and then lipid raft preparations made. Fractions 3, 4 
(raft), and 10, 11 (cytosolic) were subjected to precipitation with avidin-Sepharose. PKCθ, 
CARMA1, MALT1, Bcl-10, FADD, RIP1, TRAF2, TRAF6, IKKα, IKKβ, and IKKγ were 
all observed exclusively in active caspase precipitates from lipid rafts, and not in the 
cytosolic fraction (Fig. 2A, right panels), even though the major portion of nearly all these 
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proteins resided in the cytosolic fraction (Fig. 2A, left panels). As negative controls, neither 
linker for activation of T cells (LAT, raft localized) (35, 36) nor paxillin (cytosol localized) 
was present in the active caspase complex (Fig. 2A, lower right panels). Further specificity 
of the assay was demonstrated by the ability of a 10-fold excess of non-biotinylated z-VAD-
fmk to compete for binding of biotin-VAD-fmk to active caspases, and hence for the ability 
to co-precipitate associating molecules such as MALT1 and Bcl-10 (Fig. 2B). Although 
MALT1 is a para-caspase, studies have shown that it does not possess caspase activity and 
does not itself bind Z-VAD-fmk (37). Formation of the active caspase complex was also 
independent of Fas expression, as the same associations were observed in Fas-deficient 
lpreffector T cells (Fig. 2C). Thus, active caspase-8 and NF-κB signaling proteins interact in 
lipid rafts of effector T cells.
Caspase-8 Is Required for Association of MALT1 and Bcl-10 in the Active Caspase 
Complex
Because biotin-VAD-fmk will bind to all active caspases, we investigated to what extent the 
presence of caspase-8 was specifically required for the association of MALT1 and Bcl-10. 
For these studies we used mice bearing a conditional deletion of caspase-8 in the T cell 
compartment. tcasp8−/−mice contain homozygous caspase-8/loxP/loxP sites and are crossed 
with lck-Cre mice (7). T cells from these mice are known to be hyporesponsive to TCR 
signals. T cells from tcasp8−/−mice or wild-type mice were stimulated with anti-CD3/CD28 
plus IL-2. On day 4 biotin-VAD-fmk lysates were made, precipitated with avidin-Sepharose, 
and immunoblotted for caspase-8, MALT1, and Bcl-10. Although whole cell lysates from 
caspase-8-deficient T cells contained similar levels of MALT1 and Bcl-10 as wild-type T 
cells (data not shown), neither of these molecules was detectable in the biotin-VAD-fmk 
precipitates from caspase-8-deficient T cells (Fig. 3A).
Because Bcl-10 and MALT1 associate via an immunoglobu-lin-like domain within MALT1 
(31), we further examined the dependence of recruitment of MALT1 and Bcl-10 to the 
active caspase complex on the presence of the other protein. Day 4 effector T cells were 
generated from Bcl-10-deficient and MALT1-deficient mice and their respective normal 
littermate controls. Active caspases were precipitated from biotin-VAD-fmk-labeled lysates, 
and immunoblots performed for caspase-8, MALT1, and Bcl-10. T cells from Bcl-10-
deficient mice, MALT1-deficient mice, and their respective wild-type controls expressed 
similar levels of total caspase-8 in whole cell lysates, as well as relatively similar amounts of 
active caspase-8 in avidin-Sepha-rose precipitates (Fig. 3, Band C). As before, Bcl-10 and 
MALT1 were both associated with active caspases in wild-type T cells. However, Bcl-10-
deficient T cells had no detectable MALT1 associated with active caspases (Fig. 3B, right 
panels). Similar findings were observed in a second experiment. This was consistent with 
the ability of MALT1 to directly associate with Bcl-10 (31, 38), which was confirmed by co-
immunoprecipitation of MALT1 with Bcl-10 (data not shown). By contrast, MALT-
deficient effector T cells still manifested Bcl-10 in the active caspase complex (Fig. 3C, 
right panels). Thus, Bcl-10 links MALT1 to the active caspase complex in effector T cells.
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The Active Caspase-8 Complex Forms Rapidly following TCR Ligation
We next examined how quickly caspase-8 activation occurs after TCR stimulation and how 
rapidly NF-κB signaling proteins associate with active caspases. Purified T cells were 
analyzed either unstimulated or following stimulation with soluble cross-linked anti-CD3 for 
30 or 60 min. Each population was then treated with biotin-VAD-fmk for an additional 15 
min prior to lysis. Active caspases were precipitated from whole cell lysates using identical 
amounts of protein (600 µg), and immunoblots performed for caspase-8, MALT1, and 
Bcl-10. As noted earlier, unstimulated T cells possessed very little active caspase-8. In 
several experiments this ranged from undetectable to the low level shown in Fig. 4A. This 
may reflect either some activation or death of T cells during their purification, or more likely 
the low levels of homeostatic proliferation of T cells in normal mice (39). Nonetheless, 
caspase-8 activation rapidly increased within 30 min of TCR stimulation (Fig. 4A). The 
levels of associated MALT1 and Bcl-10 also rapidly increased proportionally with the levels 
of active caspase-8. These data reveal that active caspase-8 rapidly complexes with members 
of the NF-κB signaling pathway following TCR ligation.
The quick activation of caspase-8 was reflected in the rapid increase of total caspase activity 
within the first couple of cell cycles following TCR ligation. Wild-type lymph node cells 
were labeled with the membrane dye CFSE and stimulated for 2 days with anti-CD3/CD28 
and then transferred to new wells containing medium plus IL-2 for an additional 24 h to 
avoid activation-induced cell death. Under these conditions dead cells comprised less than 
1% of T cells. Day 3 effector T cells were then sorted based on the number of cell divisions, 
and caspase activity was determined. Undivided T cells possessed negligible levels of 
caspase activity, comparable with naïve T cells (Fig. 4B) (4). By contrast, substantial levels 
of caspase activation were generated within 1–2 cell divisions, and this increased only 
minimally with further cell divisions. These findings are consistent with the early 
appearance of an active caspase complex following T cell activation, and with persistence of 
an active caspase complex in effector T cells. Furthermore, early caspase activity was 
necessary for full activation of NF-κB. Using mice that transgenically express the NF-κB 
binding site linked to a luciferase reporter (24, 25), caspase blockade with z-VAD-fmk 
attenuated NF-κB activity in activated T cells (Fig. 4C). The findings were consistent in 
three experiments.
Cholesterol Depletion of Lipid Rafts Disrupts Formation of the Active Caspase-8 Complex
Because the active full-length caspase-8 that rapidly forms in lipid rafts after T cell 
activation is sustained in day 4 effector T cells and associates with NF-κB signaling 
molecules, we tested whether disruption of lipid rafts would inhibit the activation of 
caspase-8. Day 4 effector T cells were treated or not treated with the cholesterol depleting 
agent MBCD for 10 min, lysed, and then fractioned into lipid raft and cytosolic 
compartments. Analysis of cell fractions revealed a decrease within the lipid raft fraction of 
LAT and caspase-8, but no change in the cytosolic location of paxillin (Fig. 5A). To disrupt 
lipid raft formation prior to activation, fresh T cells were pretreated or not treated with 
MBCD for 10 min followed by TCR stimulation for 60 min using crosslinked anti-CD3. In a 
similar manner, day 4 effector T cells were treated or not treated with MBCD for 10 min in 
the absence of further TCR stimulation. Each population was then incubated with biotin-
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VAD-fmk for an additional 15 min to label active caspases, and lysed. An equivalent 
amount of input protein (600 µg) from each population was used to precipitate active 
caspases and then immunoblotted for caspase-8, MALT1, Bcl-10, and caspase-3. The data 
show a clear reduction of full-length active caspase-8 from fresh T cells pretreated with 
MBCD prior to TCR stimulation for 60 min, as well as from day 4 effector T cells treated 
with MBCD before lysis (Fig. 5B). Likewise, the association of MALT1 and Bcl-10 with 
active caspases decreased upon disruption of lipid rafts. No active caspase-3 was detectable 
in fresh T cells after 60 min of TCR activation, regardless of MBCD treatment, indicating 
that caspase-8 activation precedes caspase-3 activation. In contrast, day 4 effector T cells did 
contain active caspase-3, consistent with previous studies (2, 4, 40). Furthermore, because 
pro-caspase-3 is activated by its cleavage, the level of active cleaved caspase-3 was not 
altered by MBCD treatment (Fig. 5B). This also served as a control that biotin-VAD-fmk 
was still able to label and precipitate active caspases in the presence of MBCD. Thus, 
activation of full-length caspase-8 is dependent on the continuous presence of intact lipid 
rafts.
DISCUSSION
The current findings demonstrate that following T cell activation there is rapid migration 
and activation of caspase-8 within lipid rafts, and in association with c-FLIPL. Increased 
expression of c-FLIPL enhances the level of active caspase-8 in T cells through the 
previously shown heterodimerization of c-FLIPL with caspase-8 (10, 29). Furthermore, c-
FLIPL is at least one immediate substrate for caspase-8 in this process. The active caspase 
complex also associates with several members of the NF-κB signaling pathway 
independently of Fas expression. This parallels previous observations that caspase activity in 
T cells is necessary for activation of NF-κB (6). Collectively, these results suggest a model 
in which TCR-induced caspase-8 activation occurs in a sequestered environment that limits 
the degree of caspase-8 activation as well as restricts the cleavage of caspase-8 substrates to 
those involved with NF-κB activation and not with cell death.
The TCR-induced association of c-FLIPL with active caspases suggests a role for c-FLIPL in 
the optimal activation of full-length caspase-8. This is consistent with structural studies 
showing that c-FLIPL contains an activation loop that interacts with the enzymatic pocket of 
caspase-8 (10). c-FLIPL is then rapidly cleaved by caspase-8 to form processed p43 FLIP (9, 
12, 41). Evidence of p43 FLIP is apparent shortly after T cell activation (3, 4) and p43 FLIP 
associates more avidly with RIP1 and TRAF2 than does full-length c-FLIPL (14, 15, 30). 
Consistent with these observations, induction of NF-κB activity by c-FLIPL requires caspase 
activity, whereas p43 FLIP activates NF-κB independently of caspase activity (30). An 
additional caspase cleavage product of c-FLIPL consisting of the 22-kDa N terminus has 
also been reported recently to interact directly with IKKγ (42). Collectively these findings 
provide at least one explanation for the requirement of caspase-8 enzymatic activity in T cell 
activation, rather than caspase-8 merely functioning as a scaffolding protein. Further support 
for the concept that caspase-8 activation is necessary for T cell proliferation comes from 
studies of humans bearing an enzymatically inactive caspase-8. T cells from these 
individuals proliferate minimally to TCR stimulation and manifest diminished activation of 
NF-κB (5, 6). Reconstitution of caspase-8-deficient Jurkat T cells with wild-type caspase-8, 
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but not inactive mutant caspase-8, restored NF-κB activation upon anti-CD3/anti-CD28 
stimulation (6). Similar defective T cell proliferation was observed in mice that lack 
caspase-8 in the T cell compartment (7). These findings are consistent with our observations 
that in the absence of caspase-8 in T cells, MALT1 and Bcl-10 were not observed in the 
active caspase complex.
The active caspase complex that forms in lipid rafts during T cell activation may serve as a 
matrix to both spatially limit the degree of caspase activation, as well as to nucleate several 
intermediaries of the NF-κB pathway. This complex includes PKCθ, CARMA1, MALT1, 
Bcl-10, RIP1, TRAF2/6, and IKKα/β/γ. Mice deficient for PKCθ, CARMA1, Bcl-10, or 
MALT1 all have deficient TCR-mediated NF-κB signaling (17, 20–22, 43). Related findings 
by Su et al.(6) demonstrated the association of Bcl-10 and the IKK complex with active 
caspases in TCR-stimulated human T cells. Our findings extend those observations by 
showing the additional association in this complex of c-FLIPL, CARMA1, and RIP1, and 
the lack of a requirement for Fas.
We also observed that in effector T cells TRAF2 and TRAF6 are associated with active 
caspases. This is consistent with recent findings by Bidère et al.(44) that TRAF6 associates 
with caspase-8 in lipid rafts. Furthermore, RNA silencing of TRAF2 or TRAF6 expression 
in Jurkat T cells caused decreased IKK activation in response to anti-CD3/anti-CD28 
stimulation (45). TRAF6 and Bcl-10 are responsible for Lys63ubiquitination of IKK , which 
is essential for TCR-mediated NF-κB signaling (45–48). Moreover, MALT1 contains two 
putative TRAF6 binding sites that, when mutated, lead to a decrease in MALT1-mediated 
IKK activation (45). TRAF2/6, MALT1, and IKK members migrate to lipid rafts following 
TCR stimulation, and expression of raft-targeted IKKγ is sufficient to directly drive IκBβ 
phosphorylation and NF-κB signaling (49). The active caspase complex we describe resides 
exclusively in lipid rafts and contains many of the components necessary for TCR-mediated 
NF-κB signaling.
It is clear that a significant portion of active caspase-8 in stimulated T cells is in its full-
length form within lipid rafts and represents only a very small portion of total cellular 
caspase-8. This is consistent with molecular modeling of caspase-8 with c-FLIPL (10, 11). A 
previous study of lipid rafts in activated T cells did not observe relocation of caspase-8 to 
lipid rafts (50). We too were initially unimpressed by the amount of caspase-8 that could be 
detected in the lipid raft fraction of day 4 effector T cells, and this was even less apparent at 
early time points. It was only after we included the additional step of selectively 
precipitating only the active caspase fraction using biotin-VAD-fmk that we observed the 
dramatic difference between active caspase-8 in the lipid raft fraction and its absence in the 
cytosolic fraction, despite the vast majority of total caspase-8 residing in the cytosolic 
fraction. Lipid raft integrity was also essential for both promoting and maintaining caspase-8 
activation as well as the associated NF-κB signaling molecules. By contrast, activation of 
pro-caspase-3 requires its cleavage, which is irreversible, and is thus maintained following 
disruption of lipid rafts. Furthermore, active caspase-3 was not detected after 60 min of TCR 
stimulation, whereas active fulllength caspase-8 was observed. These data indicate that 
caspase-3 is not likely responsible for activating full-length caspase-8 nor for the association 
of MALT1 and Bcl-10 to active caspase complexes, and are also consistent with the studies 
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showing normal T cell activation in caspase-3-deficient mice (51). Thus, confining active 
caspases to lipid rafts may protect effector T cells from unrestricted proteolysis of target 
proteins that are normally cleaved during Fas-mediated apoptosis, such as Bid (1, 4, 40), 
whereas at the same time promoting cleavage of other substrates, such as c-FLIPL (4, 12, 
41), that can promote NF-κB activation.
Although the active caspase complex begins to form in lipid rafts within 30 min of TCR 
ligation, it clearly persists to the day 4 effector T cell stage. Previous studies revealed that 
naïve T cells have relatively small lipid rafts at the plasma membrane, whereas they contain 
a considerable intracellular raft component (52, 53). Upon TCR activation, surface lipid rafts 
increase in size and stability, and contain greater concentrations of selected signaling 
molecules (53–55). For example, a portion of total cellular Lck shifts from an intracellular 
localization in naïve T cells to the plasma membrane in association with CD8 in effector T 
cells, and this association is maintained in memory T cells (56). In another study, effector 
CD4+ T cells at day 5 continued to exhibit CD4, LAT, Fyn, and Lck in the lipid raft 
fractions, indicating that several signaling molecules remain stably associated with lipid 
rafts for prolonged periods of time (27). Our results showing the active caspase complex in 
day 4 effector T cells support these findings and are consistent with the known persistence 
of NF-κB activity in effector T cells (27). However, once caspase-8 and c-FLIPL association 
is disrupted, as with cholesterol depletion of lipid rafts, the activity of caspase-8 is greatly 
reduced, despite no change in total cellular levels of caspase-8. The biological role for 
maintaining active caspase-8 in the effector T cell stage is uncertain at present. One 
possibility may be to maintain NF-κB signaling molecules complexed in a subcellular 
location in proximity to the TCR signaling machinery, thereby decreasing the lag time 
between repeated TCR ligation and NF-κB signaling. Another possibility is that continued 
caspase activity may be important to ensure that T cells undergo apoptosis if repeatedly 
stimulated during their effector stage. Activation-induced cell death might drive the 
intermediate levels of effector caspases to a point that is incompatible with cell survival. 
This would resemble the findings with c-FLIPL-Tg T cells in which augmented caspase 
activity results in both more rapid cell cycling as well as more rapid cell death (29).
At present it is uncertain how the active caspase complex is recruited to lipid rafts. One 
possibility would be the migration of caspase-8 to death receptors following TCR ligation. 
Although Fas also migrates to lipid rafts during the induction of cell death by Fas ligand 
(26), we found TCR-induced caspase activation and recruitment of the NF-κB signaling 
molecules to be independent of Fas. We have also not detected Fas in the active caspase 
complex in wild-type T cells.5We are currently investigating whether other death receptors, 
such as TNFR1 or TRAIL receptors, are required for caspase activation in T cells. A 
somewhat similar complex involving RIP1 and TRAF2 has been observed shortly following 
stimulation of TNFR1 to activate NF-κB, which later recruits caspase-8 to promote cell 
death (57). A recent study has suggested that TRAF6 is responsible for localization of 
caspase-8 to lipid rafts (44). An additional candidate would be CARMA1, which contains a 
PDZ domain that is responsible for recruitment of MALT1 and Bcl-10 to lipid rafts (31).
5J. Q. Russell, unpublished observations.
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The exact role for c-FLIPL in modulating cell death and NF-κB signaling remains unclear. 
Transient transfection of c-FLIPL was shown to induce spontaneous activation of NF-κB in 
a caspase-8-dependent manner (30). By contrast, c-FLIP-deficient T cells manifested the 
normal ability to activate NF-κB (58). Furthermore, transfection of c-FLIPL into some cell 
lines inhibited Fas ligand-mediated secretion of IL-8 and other known NF-κB target genes 
(59). Caspase blockade did not inhibit IL-8 production in response to Fas ligation, indicating 
that caspase activity may not be necessary for the expression of certain NF-κB-responsive 
genes following Fas ligation, where caspase activation is strong, but is required for TCR-
induced NF-κB signaling where caspase activation is substantially less (59). Non-apoptotic 
effector T cells maintain moderate levels of caspase activity compared with the high levels 
of caspase activity generated following Fas stimulation (4). In the case of TCR-mediated 
caspase-8 activation, c-FLIPL likely plays an important role in caspase-8 activation, and p43 
FLIP may more effectively recruit NF-κB signaling molecules than full-length c-FLIPL (9–
11). In contrast, when Fas is ligated, caspase-8 activation can be inhibited by c-FLIP-
mediated competition with caspase-8 for recruitment to FADD, and thus potentially 
blocking the recruitment of NF-κB signaling molecules (60). Further studies are necessary 
to resolve these apparent discrepancies between active caspase complexes formed following 
Fas versusTCR ligation.
The current model suggests certain predictions regarding how c-FLIPL regulates T cell 
activation. One is that c-FLIPL is pivotal to the regulation of caspase-8 activation and hence 
proliferation of primary T cells. Consistent with this idea is the finding that increased 
expression of c-FLIPL in T cells leads to both enhanced caspase activity as well as increased 
proliferation (15, 16). T cell proliferation and survival are also severely reduced in the 
absence of c-FLIP (58, 61). Given the relatively ubiquitous expression of caspase-8 and c-
FLIPL, a similar molecular complex may be critical for the growth or development of a 
variety of cell types, as demonstrated in neurons (62), endothelial cells (63), monocytes (63, 
64), and bone marrow stromal stem cells (65).
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FIGURE 1. Active full-length caspase-8 and c-FLIP are present in lipid rafts of effector, but not 
fresh T cells
Wild-type and c-FLIPL-Tg fresh and day 4 effector T cells were treated with biotin-VAD-
fmk prior to lysis. Lipid raft and cytoplasmic compartments were isolated in 12 1-ml 
fractions as described under “Experimental Procedures.” A, cytosolic and lipid raft fractions 
were identified by immunoblots for control proteins paxillin (cytosolic) and GM1 (raft). 
Immunoblots were also performed for caspase-8 and c-FLIP to determine cellular 
localization in wild-type (left) and c-FLIPL-Tg (right) T cells. B, 800 µl of lipid raft fraction 
4, or cytosolic fractions 10 and 11, of fresh or day 4 wild-type effector T cells were 
incubated with streptavidin-Sepharose beads and immunoblot analysis performed on 
precipitates to identify active full-length caspase-8 and cleaved p43 caspase-8, as well as 
full-length c-FLIPL and processed p43 FLIP. Lipid raft fractions from fresh and day 4 
effector populations contained comparable amounts of protein. Whole cell lysate (WCL) 
from day 4 effector T cells was included as a positive control. Data are representative of 
three experiments.
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FIGURE 2. NF-κB signaling molecules associate with active caspases in lipid rafts of effector T 
cells
A, wild-type day 4 effector T cells were labeled with biotin-VAD-fmk, lysed, and separated 
into lipid raft (3and 4) and cytosolic (10and 11) 1-ml fractions. 50 µl of each fraction were 
separated by SDS-PAGE and immunoblotted for the indicated molecules (left side panels). 
800 µl of the same fractions were then treated with streptavidin-Sepharose and active 
caspase precipitates were separated and immunoblotted for the same molecules (right side 
panels). LAT was included to demonstrate that not every raft-associated molecule was 
associated with active caspases. NS, non-specific band. B, effector T cells were treated with 
biotin-VAD-fmk with or without 10-fold excess of non-biotinylated Z-VAD-fmk prior to 
lysis. Active caspase precipitates were immunoblotted for MALT1 and Bcl-10. C, active 
caspases were precipitated from wild-type (WT) and Fasdeficient lprday 4 effector T cells 
and immunoblotted for the indicated molecules. Results shown are from two independent 
experiments. WCL, whole cell lysate.
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FIGURE 3. Bcl-10 is necessary for recruitment of MALT1 to active caspase complexes
Effector T cells were generated from tcasp8−/− mice and wild-type controls (WT) (A) and 
Bcl-10−/− mice and their normal littermate wild-type controls (B), or MALT1−/−mice and 
their normal littermate wild-type controls (C), and labeled with biotin-VAD-fmk, lysed, and 
active caspases precipitated. Immunoblot analysis was performed for caspase-8, Bcl-10, and 
MALT1 on whole cell lysates (left) and streptavidin-Sepharose precipitates of active 
caspases (right). Results are representative of two independent experiments.
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FIGURE 4. Rapid formation of active caspase complex following TCR ligation and requirement 
of active caspases for NF-κB activation
A, wild-type resting T cells were either unstimulated (Un) or stimulated with soluble anti-
CD3 cross-linked with goat anti-hamster IgG for 30 and 60 min and then treated with biotin-
VAD-fmk for an additional 15 min before lysis. Active caspases were precipitated from 600 
µg of whole cell lysates and immunoblots performed for caspase-8, MALT1, and Bcl-10. 
Results shown are from one of three independent experiments. B, wild-type lymph node 
cells were labeled with the membrane dye CFSE followed by stimulation with anti-CD3/
anti-CD28 for 2 days. Cells were then transferred to new wells containing fresh medium 
plus IL-2 for an additional 24 h. T cells were identified by surface staining CD4 plus CD8 
and sorted based on the number of cell cycles completed. A caspase activity assay using 
DEVD-rhodamine was then performed on each population. C, T cells from NF-κB-
luciferase reporter mice were activated with anti-CD3/anti-CD28 plus IL-2 in the presence 
of Me2SO vehicle control (untreated) or Z-VAD (100 µM). After 48 h cells were analyzed 
for luciferase activity. Results shown are from one of three experiments. Differences were 
statistically significant by paired ttest (p < 0.05). WCL, whole cell lysate.
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FIGURE 5. Cholesterol depletion displaces caspase-8 from lipid rafts and disrupts the activation 
of full-length caspase-8 and association of MALT1 and Bcl-10 with active caspases
A, day 4 wild-type effector T cells were treated with 20 mM (+) or not treated (−) for 10 min 
prior to lysis. Lipid raft (fraction 4) and cytosolic (fractions 10 and 11) compartments were 
isolated and immunoblots performed for paxillin, LAT, and caspase-8. B, fresh and effector 
T cells were either treated or not treated for 10 min with 20 mM MBCD. Fresh cells were 
then stimulated with soluble anti-CD3 cross-linked with goat anti-hamster for 60 min. 
Effector and short term-stimulated T cells were subsequently treated with biotin-VAD-fmk 
for 15 min, and active caspases were precipitated from 600 µg of total cellular protein and 
immunoblotted for caspase-8, MALT1, Bcl-10, and caspase-3. Empty laneswithin the same 
gel and exposure were electronically removed to allow approximation of the samples of 
interest. WCL, whole cell lysate.
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